| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000024144 |
| Receipt No. | R000027798 |
| Official scientific title of the study | Clinical evaluation study of newly developed microsatellite instability test kit |
| Date of disclosure of the study information | 2016/09/23 |
| Last modified on | 2017/10/05 (Ver. 3) |
| Basic information | ||
| Official scientific title of the study | Clinical evaluation study of newly developed microsatellite instability test kit | |
| Title of the study (Brief title) | GI-SCREEN-CRC-MSI substudy 01 | |
| Region |
|
|
| Condition | ||||
| Condition | Advanced / recurrent colorectal cancer | |||
| Classification by specialty |
|
|||
| Classification by malignancy | Malignancy | |||
| Genomic information | YES | |||
| Objectives | |
| Narrative objectives1 | To evaluate the concordance between the standard method of MSI test using both tumor and normal samples and the newly developed MSI test kit using only tumor samples |
| Basic objectives2 | Others |
| Basic objectives -Others | To compare the positive and negative concordance rate between standard genetic tastings and a newly developed MSI test kit |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | To evaluate sensitivity (positive concordance rate) and specificity (negative concordance rate) between the standard method using both tumor and normal samples and the newly developed MSI test kit using only tumor samples |
| Key secondary outcomes | |
| Base | |
| Study type | Observational |
| Study design | |
| Basic design | |
| Randomization | |
| Randomization unit | |
| Blinding | |
| Control | |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | |
| No. of arms | |
| Purpose of intervention | |
| Type of intervention | |
| Interventions/Control_1 | |
| Interventions/Control_2 | |
| Interventions/Control_3 | |
| Interventions/Control_4 | |
| Interventions/Control_5 | |
| Interventions/Control_6 | |
| Interventions/Control_7 | |
| Interventions/Control_8 | |
| Interventions/Control_9 | |
| Interventions/Control_10 | |
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | Patients registered in GI-SCREEN CRC-MSI (UMIN000020437) and meet the following criteria;
1) Patients who agreed to the secondary usage of specimen when they agreed to GI-SCREEN CRC-MSI, and did not revoked their agreements. 2) Patients whose MSI status were decided by both tumor and normal samples in GI-SCREEN CRC-MSI 3) Sufficient quantity of DNA were extracted from patients' tumor sample for newly developed MSI test kit |
|||
| Key exclusion criteria | 1) Patients judged as inappropriate for this study by investigator | |||
| Target sample size | 300 | |||
| Research contact person | |
| Name of lead principal investigator | Takayuki Yoshino |
| Organization | National Cancer Center Hospital East |
| Division name | Department of Gastroenterology and Gastrointestinal Oncology |
| Address | 6-5-1, Kashiwanoha, Kashiwa, Chiba, 277-8577 Japan |
| TEL | 04-7133-1111 |
| tyoshino@east.ncc.go.jp | |
| Public contact | |
| Name of contact person | Hideaki Bando |
| Organization | National Cancer Center Hospital East |
| Division name | Department of Gastroenterology and Gastrointestinal Oncology |
| Address | 6-5-1, Kashiwanoha, Kashiwa, Chiba, 277-8577 Japan |
| TEL | 04-7133-1111 |
| Homepage URL | |
| hbando@east.ncc.go.jp | |
| Sponsor | |
| Institute | FALCO biosystems Ltd. |
| Institute | |
| Department | |
| Funding Source | |
| Organization | FALCO biosystems Ltd. |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | Five mononucleotides microsatellite marker, NR21, BAT26, BAT25, NR24 and MONO27, were utilized by newly developed MSI test kit. |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000027798 |